Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nitric oxide (NO)/cGMP pathway is known as a mediator in anxiety modulation. In this study, we assessed the involvement of NO pathway in the estrous cycle-related changes of anxiety level in rat. By using elevated plus-maze test, we studied the changes of serum nitrate and nitrite (NO(x)) levels in comparison to the estrous cycle-dependent changes of
anxiety state
. Then, we tested the effects of nitric oxide synthase (NOS) inhibitor, L-
NAME
(10, 60mg/kg, i.p.), and the NO precursor, l-arginine (100mg/kg, i.p.) on anxiety modulatory properties of exogenous ovarian hormones in ovariectomized (OVX) rats. Compared with other cycle phases and with OVX rats, cycling rats spent more time in open arms and had lower levels of serum NO(x) levels during metestrous while they spent less time in open arms and had lower levels of serum NO(x) levels during proestrous. In OVX rats, L-
NAME
(60mg/kg, i.p.) exerted anxiolytic effect while l-arginine showed no effect. In comparison with corn oil-treated controls, estradiol benzoate (10microg/kg, subcutaneously (s.c.)) significantly increased the serum NO(x) level and exerted anxiogenic effect, which was dose-dependently inhibited by L-
NAME
but was not changed by l-arginine. In contrast, progesterone (25mg/kg, s.c.) significantly decreased the serum NO(x) level and exerted anxiolytic effect, which was abolished by l-arginine but was not affected by L-
NAME
. These findings suggest that NO system might be involved in the estrous cycle-related changes of anxiety level, probably by mediating the effect of ovarian sex hormones.
...
PMID:Nitric oxide involvement in estrous cycle-dependent changes of the behavioral responses of female rats in the elevated plus-maze test. 1720 42
